Clinical data | |
---|---|
Routes of administration | Topical |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H22N4O2 |
Molar mass | 314.389 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel [1] in the treatment of skin lesions [2] such as those caused by the herpes simplex virus [3] [4] and cutaneous T cell lymphoma, [5] and as an adjuvant to increase the effectiveness of vaccines. [6] In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. [7] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, [8] and an upregulator of the opioid growth factor receptor. [9] On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma. [10]
Clinical data | |
---|---|
Routes of administration | Topical |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H22N4O2 |
Molar mass | 314.389 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel [1] in the treatment of skin lesions [2] such as those caused by the herpes simplex virus [3] [4] and cutaneous T cell lymphoma, [5] and as an adjuvant to increase the effectiveness of vaccines. [6] In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. [7] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, [8] and an upregulator of the opioid growth factor receptor. [9] On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma. [10]